RhumbLine Advisers’s CervoMed CRVO Stock Holding History

RhumbLine Advisers’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,830	Closed	-$53.3K	–	4165
2025 Q1	$53.3K	Buy	5,830 +1,526	+35%	+$5.81K	﹤0.01%	3557
2024 Q4	$10.1K	Sell	4,304 -248	-5%	-$2.41K	﹤0.01%	3882
2024 Q3	$66.5K	Sell	4,552 -1,075	-19%	-$16.7K	﹤0.01%	3625
2024 Q2	$96.3K	Buy	+5,627	New	+$123K	﹤0.01%	3523

Other funds holding CRVO

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return

AAS

Avantax Advisory Services Dallas, Texas $18.2B AUM 15.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RhumbLine Advisers's CRVO Position: Q2 2025 in Review

RhumbLine Advisers sold out of CervoMed (CRVO) in Q2 2025, closing a stake of 5,830 shares — an estimated $53.3K sold.

RhumbLine Advisers first reported a position in CRVO in Q2 2024 and held it in 4 quarters. The position peaked at $96.3K in Q2 2024. 45 funds tracked by Wall St. Rank hold CRVO as of Q2 2025.

RhumbLine Advisers reported no remaining CervoMed position as of Q2 2025 after selling out during the quarter.
RhumbLine Advisers sold 5,830 CervoMed shares in Q2 2025, an estimated $53.3K.
RhumbLine Advisers first reported a position in CervoMed in Q2 2024 and held it in 4 quarters.
RhumbLine Advisers's CervoMed position peaked at $96.3K in Q2 2024.
45 funds tracked by Wall St. Rank held CervoMed as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.